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All adaptive immune responses are ini-
tiated by dedicated antigen-presenting 
cells (APCs), mainly dendritic cells (DC), 
whose principal purpose is the activation 
of T-cells. To this end, APCs need to cor-
rectly perform a series of complex func-
tions: First, they need to home to tissues 
to be available for collecting antigens. 
Then they need to transport the antigen 
to secondary lymphatic organs, where naïve 
T-cells await activation. The antigen must 
be endocytosed and loaded onto MHC 
molecules to be visible to T-cell receptors, 
necessitating the existence of a specialized 
antigen processing machinery. Antigenic 
peptides for presentation to CD4+ T helper 
and CD8+ T effector cells have their own 
rules of Ag-processing: to generate MHC 
class II-peptides for T helper cell activa-
tion, APCs take up exogenous protein Ags, 
proteolytically process it in late endosomes, 
load nascent MHC class II molecules with 
“fitting” peptides, and export the MHC 
class II-peptide complex to the cell mem-
brane for presentation to T helper cells. In 
contrast, canonical MHC class I-peptides 
for CD8+ T-cell activation are generally 
derived from intracellularly synthesized 
(endogenous) proteins that first undergo 
a proteasomal processing pathway before 
fitting peptides are loaded on MHC class I 
molecules and presented to CD8+ T-cells. 
This restriction of MHC class I loading, 
however, can be overcome by a process 
termed “cross-presentation,” which allows 
exogenous Ag to “cross” into the MHC class 
I pathway for activation of CD8 T-cells. The 
recent clarification of some underlying 
molecular mechanisms has ended the long 
controversy regarding cross-presentation. 
It was shown that only distinct DCs charac-
terized by expression of CD8α, XCR1, and 
the transcription factor Batf3, can cross-
present. Such DC’s sequester the MHC class 
I loading machinery for exogenous Ag to 
phagosomes and early (recycling) endo-
somes that are  supplied with Ag by specific 
receptors such as the mannose receptor or 
Clec9a. Especially the research field of DC 
subsets is developing rapidly.
In addition to antigen, APCs also need 
to deliver co-stimulatory signals that are 
required for immunogenic T-cell activa-
tion. These signals are expressed depend-
ing on recognition of molecular patterns 
indicating the presence of microbes or any 
forms of danger, implying that APCs must 
possess a range of sensors to detect such 
patterns. The lack of such patterns, and 
consequently of co-stimulation, is thought 
to result in T-cell tolerance. As this is the 
situation for self-antigens, it has been spec-
ulated that induction of peripheral T-cell 
tolerance is another central function of 
APCs. The classical “signal 1/2” theory by 
Cohn and Bretscher is still used to explain 
how APCs induce either immunity or toler-
ance. Subsequently, it has been realized that 
APCs not merely switch on T-cells, but in 
addition program them to perform distinct 
functions appropriate for defense against 
the great variety of viruses, bacteria, fungi, 
and parasites we are facing incessantly. The 
signals determining T-cell functional dif-
ferentiation have been referred to as “sig-
nal 3.” The recent discovery that APCs use 
distinct chemokines to attract naïve T-cells 
has been interpreted as a distinct signal for 
T-cell activation acting before signals 1, 2, 
and 3, which therefore has been coined “sig-
nal 0.” Finally, APCs also affect the func-
tions of effector T-cells infiltrating infected 
or inflamed tissues, for example by produc-
ing cytokines and chemokines.
This short summary of APC-function 
may create the impression that most of the 
complex functions of APCs in the induc-
tion of adaptive immunity and in avoid-
ing autoimmunity are well understood. 
However, on closer inspection there can be 
no doubt that our knowledge on the exact 
mechanisms governing APC-function is 
superficial at best. For  example, many 
different classifications of DCs currently 
co-exist, which partially overlap, and not 
always reflect on true cellular lineages, 
but are sometimes based only on cell 
surface markers. The nomenclature of 
DCs has been developed separately from 
that of macrophages, which also possess 
potent antigen-presenting functionality. 
Furthermore, the definitions of DCs and 
macrophages overlap, and it is unclear 
whether a line can be drawn and where. 
“The enigmatic signal 2” that decides 
between immunogenic and tolerogenic 
T-cell activation includes, but is not equal 
to B7 molecules, and thus remains to be 
identified. So do the pattern-recognition 
and interpretation mechanisms that APCs 
use to decide whether to express signal 2 or 
not, and to produce signal 3. Furthermore, 
if an APC carries both self-antigens and 
microbial antigens that have caused its 
maturation, will its maturation state also 
apply to the self-antigen, so that it is pre-
sented in an immunogenic manner? This 
and many other central questions remain 
unresolved.
We challenge the field to tackle our top 10 
unresolved questions in APC biology:
1. Advancing methodology and tech-
niques to study APC-function, for 
example single immune cell tracking 
techniques.
2. Understanding ontogenesis of APC 
types and subsets; developing a simpli-
fied classification based on functional 
and ontogenic, rather than phenotypic 
qualities.
3. Understanding Cell-biology and 
Biochemistry of antigen proces-
sing, especially for MHC I-restricted 
cross-presentation; for example how 
are antigens transported over orga-
nelle membranes within APC’s?
4. Identifying signal 2 that decides 
between immunity and tolerance; for 
example clarify the role of DC-derived 
IL-2.
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 8. Clarify the role of tissue-resident APCs 
during the T-cell effector phase, inclu-
ding non-hematopoietic cells with 
APC-functionality.
 9. Develop prospects of DC cell therapies.
10. Most likely the development of rationale 
vaccines will be one of the key para-
digms of the twenty-first century. We 
anticipate that deciphering the molecu-
lar APC Biology will be precondition to 
realizing this most challenging objective.
5. Unravel the pattern-recognition and 
interpretation mechanism of APCs 
resulting in the expression of signal 2.
6. Deciphering “pattern-recognition” 
signal pathways that result in signal 3: 
APC-driven Th-1, Th-2, Th-17, and 
Treg polarization.
7. Understanding the mechanisms gover-
ning APC migration from BM through 
blood into tissues, and on to secondary 
lymphatics.
